Abbonarsi

Self-sizing radiofrequency ablation balloon for eradication of Barrett's esophagus: results of an international multicenter randomized trial comparing 3 different treatment regimens - 19/08/19

Doi : 10.1016/j.gie.2019.05.023 
Kamar Belghazi, MD 1, Roos E. Pouw, MD, PhD 1, Arjun D. Koch, MD, PhD 2, Bas L.A.M. Weusten, MD, PhD 3, Erik J. Schoon, MD, PhD 4, Wouter L. Curvers, MD, PhD 4, Annieke W. Gotink, MD 2, Nahid Mostafavi, PhD 5, Rehan J. Haidry, MD, PhD 6, Oliver Pech, MD, PhD 7, Jacques J.G.H.M. Bergman, MD, PhD 1, ⁎, Raf Bisschops, MD, PhD 8
1 Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands 
2 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands 
3 Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, the Netherlands 
4 Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, the Netherlands 
5 Biostatistical Unit, Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, thhe Netherlands 
6 Department of Gastroenterology, University College Hospital NHS Foundation Trust, London, UK 
7 Department of Gastroenterology and Interventional Endoscopy, St. John of God Hospital, Regensburg, Germany 
8 Department of Gastroenterology and Hepatology, UZ Gasthuisberg, Leuven, Belgium 

∗Reprint requests: Jacques Bergman, MD, PhD, Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.Department of Gastroenterology and HepatologyAmsterdam University Medical CenterMeibergdreef 9AZ Amsterdam1105the Netherlands

Abstract

Background and Aims

Recently, the 360 Express radiofrequency ablation balloon catheter (360 Express, Medtronic, Minneapolis, Minn, USA) has replaced the traditional system for circumferential radiofrequency ablation (RFA) of Barrett’s esophagus (BE). The aim was to compare 3 different ablation regimens for the 360 Express.

Methods

An international multicenter noninferiority randomized controlled trial was conducted in which patients with a BE (2-15 cm) with dysplasia or early cancer were randomly assigned to the standard (1 × 10 J/cm2-clean-1 × 10 J/cm2), simple-double (2 × 10 J/cm2-no clean), or simple-single ablation regimen (1 × 10 J/cm2-no clean). The primary outcome was the percentage endoscopically visual BE regression at 3 months. Secondary outcomes were procedure time, adverse events, and patient discomfort.

Results

Between September 2015 and October 2017, 104 patients were enrolled. The simple-double ablation arm was closed prematurely because of a 21% stenosis rate. The trial continued with the standard (n = 37) and simple-single arm (n = 38). Both arms were comparable at baseline. Noninferiority of the simple-single arm could not be demonstrated: BE regression was 73% in the simple-single arm versus 85% in the standard arm; the median difference was 13% (95% confidence interval, 5%-23%). The procedure time was significantly longer in the standard arm (31 vs 17 minutes, P < .001). Both groups were comparable with regard to adverse events and patient discomfort.

Conclusions

This randomized trial shows that circumferential RFA with the 360 Express using the simple-double ablation regimen results in an unacceptable high risk of stenosis. Furthermore, the results suggest that a single ablation at 10 J/cm2 results in inferior BE regression at 3 months. We therefore advise using the standard ablation regimen (1 × 10 J/cm2-clean-1 × 10 J/cm2) for treatment of BE using the 360 Express. (Clinical trial registration number: NTR5191.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : 360 Express, BE, CI, DSMB, EID, ER, m-ITT, IQR, MEC, RFA, SD, WLE


Mappa


 If you would like to chat with an author of this article, you may contact Dr Bergman at [email protected].
 DISCLOSURE: Dr Koch has received research support from Cook Medical and Interscope and speaker and consultancy fees from ErbeElektromedizin. Dr Weusten has received research support and speaker fees from Pentax Medical. Dr Schoon has received speaker and consultancy fees from Medtronic, Boston Scientific, and Olympus, and research support from Fujifilm. Dr Haidry has received research support from Cook Medical, Pentax Europe, Medtronic, Beamline Technologies, and C2 Therapeutics. Dr Pech has received speaker fees from Medtronic, Olympus, Fujifilm, Boston Scientific, Falk, AbbVie, Bristol Myers Squibb, and Creo Medical. Dr Bergman has received research support from Medtronic, Olympus Endoscopy, Cook Medical, Boston Scientific, Erbe Medical, C2 Therapeutic, and Ninepoint Medical, and consultancy fees from Cook Medical and Boston Scientific. Dr Bisschops has received research support from Pentax, Fujifilm, and Cook Medical, speaker fees from Medtronic and Pentax, and consultancy fees from Medtronic, Pentax, Fujifilm, and Boston Scientific. All other authors disclosed no financial relationships relevant to this publication.
 See CME section, p. 506.


© 2019  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 90 - N° 3

P. 415-423 - settembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Classification for invasion depth of esophageal squamous cell carcinoma using a deep neural network compared with experienced endoscopists
  • Kentaro Nakagawa, Ryu Ishihara, Kazuharu Aoyama, Masayasu Ohmori, Hiroko Nakahira, Noriko Matsuura, Satoki Shichijo, Tsutomu Nishida, Takuya Yamada, Shinjiro Yamaguchi, Hideharu Ogiyama, Satoshi Egawa, Osamu Kishida, Tomohiro Tada
| Articolo seguente Articolo seguente
  • Improving patient safety in the endoscopy unit: utilization of remote video auditing to improve time-out compliance
  • Kara Raphael, Sara Cerrone, Edward Sceppa, Patricia Schneider, Tara Laumenede, Ann Lynch, Divyesh V. Sejpal

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.